Y-J. Bang

Pohang University of Science and Technology — South Korea

Medicine · Health Sciences

21h-index1.6kcitations74works2.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastric Cancer Management and Outcomes(25), Colorectal Cancer Treatments and Studies(14), Cancer Immunotherapy and Biomarkers(9), Pancreatic and Hepatic Oncology Research(8), HER2/EGFR in Cancer Research(8)

Publications74 total

Mobile application-based lifestyle intervention for improving glycemic control and body composition in manufacturing company employees in South Korea
Diabetology & Metabolic Syndrome·2025Open Access
2973P Prognostic significance of POU2F3 expression in thymic epithelial tumors
Annals of Oncology·2025
2967O Perioperative pembrolizumab for locally advanced thymic epithelial tumors
Annals of Oncology·2025
1451P Neoadjuvant and adjuvant pembrolizumab (pembro) + chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study
Annals of Oncology·2024
LBA3 Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer
Annals of Oncology·2024· 12 citedOpen Access
140P Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Annals of Oncology·2023Open Access
134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Annals of Oncology·2023· 4 citedOpen Access
LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study
Annals of Oncology·2023· 34 citedOpen Access
LBA81 Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Annals of Oncology·2023· 2 citedOpen Access
LBA82 Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Annals of Oncology·2023· 2 citedOpen Access
1382P Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer
Annals of Oncology·2021· 1 cited
195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Annals of Oncology·2020· 5 citedOpen Access
381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Annals of Oncology·2020· 2 cited
197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Annals of Oncology·2020· 2 cited
198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Annals of Oncology·2020· 11 citedOpen Access
1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
Annals of Oncology·2020· 42 citedOpen Access
1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062
Annals of Oncology·2020· 15 citedOpen Access
1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Annals of Oncology·2020· 7 cited
147P Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours
Annals of Oncology·2020· 1 citedOpen Access
SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Annals of Oncology·2019· 13 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Kohei Shitara(11), Eric Van Cutsem(8), Jaffer A. Ajani(8), Peter C. Enzinger(7), David H. Ilson(7), Florian Lordick(7), Tae‐Yop Kim(6), Sun Young Rha(5), Do‐Youn Oh(5), Daniel V.T. Catenacci(5), Ahsan M. Arozullah(5), R-H. Xu(5), J.W. Park(5), S-A. Im(4), Dae Seog Heo(4), Eui Kyu Chie(4), D-Y. Oh(3), Kyung-Woo Lee(3), Seng Hua Lee(3), Seock‐Ah Im(3)